SGFE.F Stock Overview
Provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 965.00 |
| 52 Week High | CHF 1,001.00 |
| 52 Week Low | CHF 837.50 |
| Beta | 0.62 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 446.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGFE.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | 0.04% |
| 1Y | n/a | -2.1% | 20.7% |
Return vs Industry: Insufficient data to determine how SGFE.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how SGFE.F performed against the US Market.
Price Volatility
| SGFE.F volatility | |
|---|---|
| SGFE.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SGFE.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SGFE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,945 | Reto Suter | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
Siegfried Holding AG Fundamentals Summary
| SGFE.F fundamental statistics | |
|---|---|
| Market cap | US$4.45b |
| Earnings (TTM) | US$125.45m |
| Revenue (TTM) | US$1.42b |
35.5x
P/E Ratio3.1x
P/S RatioIs SGFE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGFE.F income statement (TTM) | |
|---|---|
| Revenue | CHF 1.27b |
| Cost of Revenue | CHF 951.09m |
| Gross Profit | CHF 320.41m |
| Other Expenses | CHF 207.72m |
| Earnings | CHF 112.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 26.27 |
| Gross Margin | 25.20% |
| Net Profit Margin | 8.86% |
| Debt/Equity Ratio | 53.1% |
How did SGFE.F perform over the long term?
See historical performance and comparison